Submitted by: Submitted by vasu123
Views: 10
Words: 843
Pages: 4
Category: Business and Industry
Date Submitted: 03/28/2016 01:53 AM
Remicade (infliximab) (Rheumatoid Arthritis) Market Size, Share, Trends,
Company Profiles, Demand, Insights, Analysis, Research, Report,
Opportunities, Segmentation and Forecast To 2023
Summary
Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and
deformity of the joints. It affects over seven million individuals in the 10MM covered in this
report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the
prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have
been effective in treating the signs and symptoms of RA and inhibiting progression to erosive
bone disease. However, the landscape is quickly changing with the introduction of biosimilars,
novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change
the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective
therapies for RA, the market is extremely competitive for new entrants and will undergo further
pressure as biosimilars are approved and launch.
Remicade (infliximab) was originally developed as a result of a collaboration between two
professors at NYU Langone Medical Center and Centocor Ortho Biotech (acquired by Janssen
Biotech, a subsidiary of J&J) (NYU Langone Medical Center, press release, August 12, 2005). It
is first-generation TNF inhibitor consisting of a chimeric IgG1 mAb that is specific for TNFa.
Remicade binds to TNFa with high affinity, neutralizing the effects of this cytokine, thus
preventing synovial inflammation and decreasing joint erosion in patients with RA.
Read Complete Report with TOC: http://www.radiantinsights.com/research/remicadeinfliximab-rheumatoid-arthritis-forecast-and-market-analysis-to-2023
Scope
- Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis,
pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed...